(%)
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
- Ownership
-
Mereo BioPharma Group plc Executive Compensation
* In original currency USD
Loading Data
|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total Amount |
|---|---|---|---|---|---|---|---|---|
| Wednesday, April 24th, 2024 | 2023 | Dr. Denise Scots-Knight Chief Executive Officer | 565,107 | 254,298 | 285,358 | 0 | 71,157 | 2,219,323 |
| Wednesday, April 24th, 2024 | 2022 | Dr. Denise Scots-Knight Chief Executive Officer | 506,809 | 304,085 | 0 | 0 | 68,219 | 2,237,247 |
| Wednesday, April 24th, 2024 | 2023 | Charles Sermon General Counsel | 415,651 | 162,104 | 99,540 | 0 | 48,031 | 1,088,249 |
| Wednesday, April 24th, 2024 | 2022 | Charles Sermon General Counsel | 372,772 | 186,386 | 0 | 0 | 51,198 | 949,889 |
| Wednesday, April 24th, 2024 | 2023 | Christine Fox Chief Financial Officer | 378,120 | 151,248 | 91,043 | 0 | 40,400 | 1,001,051 |
| Wednesday, April 24th, 2024 | 2022 | Christine Fox Chief Financial Officer | 332,833 | 166,416 | 0 | 0 | 40,063 | 810,939 |
